Anzeige
Mehr »
Login
Sonntag, 21.04.2024 Börsentäglich über 12.000 News von 689 internationalen Medien
Hammer-Meldung! Löst diese Meldung den nächsten Hype aus?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 883035 | ISIN: US8816242098 | Ticker-Symbol: TEV
Tradegate
19.04.24
18:42 Uhr
12,100 Euro
0,000
0,00 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
TEVA PHARMACEUTICAL INDUSTRIES LTD Chart 1 Jahr
5-Tage-Chart
TEVA PHARMACEUTICAL INDUSTRIES LTD 5-Tage-Chart
RealtimeGeldBriefZeit
12,05012,10020.04.
12,05012,10019.04.

Aktuelle News zur TEVA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrAlvotech, Teva signs deal to expand access for Humira biosimilar in U.S.22
DoTEVA PHARMACEUTICAL INDUSTRIES LTD - 8-K, Current Report21
MiBoosted by $19M equity package, Teva's Richard Francis joins upper echelons of pharma CEO pay ranks19
MiStelara biosimilar from Alvotech, Teva approved by FDA8
MiAlvotech and Teva gain FDA approval of Selarsdi for psoriasis13
MiTeva CEO Francis becomes highest paid TASE co exec20
MiAlvotech And Teva: FDA Approves Selarsdi Injection For Psoriasis And Psoriatic Arthritis32
MiTeva, Alvotech rise as FDA approves Stelara biosimilar124
DiTeva Pharmaceutical Industries Limited: Alvotech and Teva Announce U.S. FDA Approval of SELARSDI (ustekinumab-aekn), biosimilar to Stelara (ustekinumab)473SELARSDI is approved for both adult and pediatric indications and is the second biosimilar approved under the strategic partnership between Alvotech and Teva SELARSDI is expected to be...
► Artikel lesen
DiTeva Confirms Austedo's Effectiveness For HD Chorea With The 4-week Titration Kit219PETAH TIKVA (dpa-AFX) - Tuesday, Teva Pharmaceutical Industries Ltd.'s (TEVA) U.S. branch, announced a favorable real-world efficacy, safety, compliance, and satisfaction for Huntington's disease...
► Artikel lesen
11.04.Teva confirms efficacy in late stage trial of its migraine treatment for adult Chinese patients27
11.04.Teva Confirms Efficacy, Safety Of AJOVY In Prevention Of Migraine218PETAH TIKVA (dpa-AFX) - Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), reported results from a Phase 3 study evaluating AJOVY for the prevention of migraine...
► Artikel lesen
06.04.Teva Pharmaceutical Industries Limited: New Pharmacokinetic Modeling Data Presented by Teva Simulates Clinical Profiles of Schizophrenia Patients Switching to UZEDY (risperidone) Extended-Release Injectable Suspension at SIRS 2024740PK modeling data provide insights into potential dosing conversions and strategies for switching to UZEDY from a long-acting injectable (LAI) formulation of risperidone microspheres (R064766)...
► Artikel lesen
05.04.Teva signs licensing deal with mAbxience for oncology biosimilar candidate22
04.04.Teva, forging ahead with new strategy, inks biosimilar deal with Spain's mAbxience14
04.04.Teva and mAbxience Enter Strategic Licensing Agreement for Biosimilar Candidate4
04.04.Teva and mAbxience sign global licensing agreement for oncology biosimilar candidate9
04.04.Teva Announces Strategic Alliance With MAbxience For Oncology Biosimilar Candidate280PETAH TIKVA (dpa-AFX) - Teva Pharmaceuticals International GmbH, a unit of Teva Pharmaceutical Industries Ltd. (TEVA) and mAbxience have entered a strategic licensing agreement for a biosimilar...
► Artikel lesen
04.04.Teva Pharmaceutical Industries Limited: Teva and mAbxience Announce Strategic Global Licensing Agreement for Oncology Biosimilar Candidate275Teva and mAbxience enter into a strategic global partnership for in-licensing of an oncology biosimilar candidate Agreement signals a major step in mAbxience's global expansion strategy...
► Artikel lesen
04.04.Why are Teva shares surging and how does it plan to keep it up30
Seite:  Weiter >>
232 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
2,1,12